PR Newswire PharmaOriginal article
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
RegulatoryVectorMist™Positive
AI Analysis
Summary
Vector Science & Therapeutics reports first quarterly results as a public company and advances VectorMist™ 510(k) submission toward FDA filing, with peptide manufacturing expected to generate revenue starting August 2026.
Outcome Details
510(k) submission advancing toward FDA filing
Importance:4/10
Sentiment:
0.30
regulatoryFDA filingearningspeptide manufacturingpublic company
Related Companies
Read the original article
Published by PR Newswire Pharma on July 24, 2026 10:37 PM